Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether her Department plans to review its current policy on the use of Evusheld in the NHS in winter 2022-23.

There are no current plans for any further review of the decision not to procure Evusheld. The decision is based on a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it is right that it has now been referred to the National Institute for Health and Care Excellence for further evaluation. At present, RAPID C-19 will continue to keep Evusheld under active review and will notify DHSC of any significant developments.